Pharmacological survey of medicinal plants for activity at dopamine receptor subtypes. II. Screen for binding activity at the D1 and D2 dopamine receptor subtypes

Pharmaceutical Biology

Volumn 41, Issue 1, 2003, Pages 45-58

  Luedtke, Robert R ^a   Freeman, Rebekah A ^a   Volk, Michael ^a   Arfan, Mohammad ^b   Reinecke, Manfred G ^c  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF PESHAWAR   (Pakistan)

^c TEXAS CHRISTIAN UNIVERSITY   (United States)

Author keywords

Dopamine receptor agonists; Dopamine receptor antagonists; Dopamine receptors; Medicinal plants

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENYLATE CYCLASE; ADIANTUM VENESTUM EXTRACT; AJUGA PARVIFLORA EXTRACT; ARTEMISIA ANOMALA EXTRACT; BELAMCANDA CHINENSIS EXTRACT; CHENOPODIUM AMBROSIODES EXTRACT; CYCLIC AMP; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; FORSKOLIN; MESSENGER RNA; MULINUM ULICINUM EXTRACT; PLANT EXTRACT; PSORALEA GLANDULOSA EXTRACT; PYRROSIA LINGUA EXTRACT; QUASSIA AMARA EXTRACT; RECEPTOR SUBTYPE; SCHINUS MOLLE EXTRACT; SENECIO RHIZOMATUS EXTRACT; TAMARINDUS INDICA EXTRACT; TARAXACUM MONGOLICUM EXTRACT; TRITIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALERIANA COARCTATA EXTRACT;

ALGA; ANIMAL CELL; ARTICLE; BOLIVIA; CHINA; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG RECEPTOR BINDING; ENZYME ASSAY; GLYCYRRHIZA; HUMAN; HUMAN CELL; LIGAND BINDING; LOTUS; MEDICINAL PLANT; NONHUMAN; PAKISTAN; PHYTOCHEMISTRY; PLANT; SEAWEED;

ADIANTUM; AJUGA; AJUGA PARVIFLORA; ALGAE; AMARA; ANIMALIA; ARTEMISIA; BELAMCANDA CHINENSIS; CHENOPODIUM; GLYCYRRHIZA; MULINUM ULICINUM; PSORALEA GLANDULOSA; PYRROSIA LINGUA; QUASSIA AMARA; SCHINUS MOLLE; SENECIO; TAMARINDUS INDICA; TARAXACUM MONGOLICUM; TRITIUM; VALERIANA;

EID: 0037302347     PISSN: 13880209     EISSN: None     Source Type: Journal    
DOI: 10.1076/phbi.41.1.45.14695     Document Type: Article

References (58)

1. Abdel-Malek S, Bastien JW, Mahler WF, Jia Q, Reinecke MG, Robinson Jr. WE, Shu YH, Zalles-Asin J (1996): Drug leads from the Kallawaya herbalists of Bolivia. 1. Background, rationale, protocol and anti-HIV activity. J Ethnopharmacol 50: 157-166.
2. Bastien JW (1987): Healers of the Andes; Kallawaya Herbalists and their Medicinal Plants. University of Utah Press, Salt Lake City.
3. Bergman J, Kamien JB, Spealman RD (1990): Antagonism of cocaine self-administration by selective dopamine D1 and D2 antagonists. Behav Pharmacol 1: 355-362.
4. Boundy VA, Luedtke RR, Molinoff PB (1993a): Development of polyclonal anti-D2 dopamine receptor antibodies to fusion proteins: Inhibition of D2 receptor-G protein interaction. J Neurochem 60: 2181-2191.
5. Boundy VA, Luedtke RR, Filtz TM, Molinoff PB (1993b): Development of anti-rat D2 dopamine receptor antibodies using sequence specific peptides. Mol Pharm 43: 666-676.
6. Boundy VA, Luedtke RR, Galitano AL, Smith JE, Filtz TM, Kallen RG, Molinoff P (1993c): Expression and characterization of the rat D3 dopamine receptor: Pharmacologic properties and development of antibodies. J Pharmacol Exp Thera 264: 1002-1011.
7. Brozoski TJ, Brown RM, Rosvoid HE, Goldman PS (1979): Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of Rhesus monkey. Science 205: 929-932.
8. Cai G, Gurdal H, Smith C, Wang H-Y, Friedman E (1999): Inverse agonist properties of dopamine antagonists at the D1a dopamine receptor: Uncoupling of the D1a dopamine receptor from Gs protein. Mol Pharmacol 56: 989-996.
9. Cardellina JH II, Munro MH, Fuller RW, Nanfredi KP, McKee TC, Tischler M, Bokesch HR, Gustafson KR, Beutler JA, Boyd MR (1993): A chemical screening strategy for the dereplication and prioritization of HIV-inhibitory aqueous natural product extracts. J Nat Prod 56: 1123-1129.
10. Cepeda C, Buchwald NA, Levine MS (1993): Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtype activated. Proc Nat Acad Sci USA 90: 9576-9580.
11. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M (1994): Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 45: 490-499.
12. Chio CL, Lajiness ME, Huff RH (1994a): Activation of heterologously expressed D3 dopamine receptors: Comparison with D2 dopamine receptors. Mol Pharmacol 45: 51-60.
13. Chio CL, Drong RF, Riely DT, Gill GS, Slinghtom JL, Huff RM (1994b): D4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells. J Biol Chem 269: 11813-11819.
14. De Lucca M, Zalles-Asin J (1992): Flora Medicinal Boliviana, Editorial Los Amigos del Libro, La Paz-Cochabamba.
15. Dearry A, Gingrich JA, Falardeau P, Fremeau Jr. RT, Bates MD, Caron MG (1990): Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 347: 72-76.
16. DeLean A, Stadel JM, Lefkowitz RJ (1980): A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem 255: 7108-7117.
17. Duke JA, Ayensu ES (1985): Medicinal Plants of China, Reference Publications, Inc., Algonac, Michigan.
18. Filtz TM, Artymyshyn RP, Guan W, Molinoff PB (1993): Paradoxical regulation of dopamine receptor in transfected 293 cells. Mol Pharmacol 44: 371-379.
19. Filtz TM, Guan W, Artymyshyn RP, Pacheco M, Ford C, Molinoff PB (1994): Mechanism of up-regulation of D2L dopamine receptors by agonists and antagonists in transfected HEK-293 cells. J Pharmacol Exp Therapeut 271: 1574-1582.
20. Girault L (1987): Kallawaya, Curanderos Itenerantes de los Andes. UNICEF, ORSTOM, La Paz, 671 pp.
21. Harborne JB (1984): Phytochemical Methods, A Guide to Modern Techniques for Plant Analysis. Chapman & Hall, London, UK.
22. Herling S, Woods JH (1980): Chlorpromazine effects on cocaine-reinforced responding in rhesus monkeys: Reciprocal modification of rate-altering effects of the drugs. J Pharmacol Exp Therapeut 214: 354-361.
23. Hu S (1980): An Enumeration of Chinese Materia Medica. The Chinese University Press, Hong Kong.
24. Kapoor LD (1990): CRC Handbook of Ayurvedic Medicinal Plants. CRC Press, Boca Raton, Florida.
25. Karlsson P, Smith L, Farde L, Harnryd C, Sedvall G, Wiesel F-A (1995): Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH 39166 in acutely ill schizophrenic patients. Psychopharmacology I21: 309-313.
26. Kenakin T (1997) Molecular Pharmacology: A Short Course. Chapter 2. Dose-Response Curves. Blackwell Sciences, Inc. Cambridge, MA.
27. Koob GF, Le HT, Creese I (1987): The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neurosci Lett 79: 315-319.
28. Lachowicz JE, Sibley DR (1997): Molecular characteristics of mammalian dopamine receptors. Pharmacol & Toxicol 81: 105-113.
29. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM (1992): L-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology 107: 394-404.
30. Lidow MS, Goldman-Rakic PS (1994): A common action of clozapine, haloperidol and remoxipride on D1- and D2-dopamine receptors in the primate cerebral cortex. Proc Nat Acad Sci USA 91: 4353-4356.
31. Lidow MS, Elsworth JD, Goldman-Rakic PS (1997): Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J Pharmacol Exp Therapeu 281: 597-603.
32. Liu F, Wan Q, Pristupa ZB, Yu XM, Wang YT, Niznik HB (2000): Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature 403: 274-280.
33. 125I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors. Synapse 38: 438-449.
34. Luedtke RR, Freeman RA, Martin MW, Bastien JW, Zalles-Asin J, Reinecke MG (2002): Pharmacological survey of medicinal plants for activity at dopamine receptor subtypes. I. Activation of D1-like receptor linked adenylyl cyclase. Pharm Biol 40: 315-325.
35. Luedtke RR, Griffin SA, Conroy SS, Jin X, Pinto A, Sesack SR (1999): Immunoblot and immunohistochemical comparison of murine monoclonal antibodies specific for the rat D1a and D1b dopamine receptor subtypes. J Neuroimmunology 101: 170-187.
36. Martin MW, Scott AW, Johnston DE Jr., Griffin SA, Luedtke RR (2001): Typical antipsychotics exhibit inverse agonist activity at D1a dopamine receptors expressed in Sf9 cells. Eur J Pharmacol 420: 73-82.
37. McGonigle P, Molinoff PB (1989): Chapter 9. Quantitative aspects of drug-receptor interaction in Basic Neurochemistry Fourth Edition (eds., Siegal G, Agranoff B, Albers RW and Molinoff P) Raven Press, New York.
38. Muller U, von Cramon DY, Pollman S (1998): D1-versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci 18: 2720-2728.
39. Nestler EJ (1994): Hard target: Understanding dopaminergic neurotransmission. Cell 79: 923-925.
40. O'Dowd BF (1993): Structures of dopamine receptors. J Neurochem 60: 804-816.
41. O'Reilly DR, Miller L, Luckow VA (1994): Baculovirus Expression Vectors: A Laboratory Manual. Oxford University Press.
42. Saloman Y, Londos C, Rodbell M (1974): A highly sensitive adenylate cyclase assay. Anal Biochem 58: 541-548.
43. Scatchard G (1949): The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51: 662-673
44. Self DW, Stein L (1992): The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats. Brain Res 582: 349-352.
45. 1- and D2-like dopamine receptor agonists. Science 271: 1586-1589.
46. Shimizu H, Daly JW, Creverling CR (1969): A radioisotopic method for measuring the formation of adenosine 3′-5′-cyclic monophosphate in incubated slices of brain. J Neurochem 16: 1609-1616.
47. Sokoloff P, Schwartz J-C (1995): Novel dopamine receptors half a decade later. TiPS 16: 270-275.
48. Su Y-F, Cubeddu LX, Perkins JP (1976): Regulation of adenosine 3′-5′-monophosphate content of human astrocytoma cells: Desensitization to catecholamine and prostaglandins. J Cyclic Nucleo Res 2: 257-263.
49. Summers MD, Smith GE (1987): A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures. Texas Agricultural Experiment Station Bulletin No. 1555.
50. Tiberi M, Caron MG (1994): High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. J Biol Chem 269: 27925-27931.
51. 1A receptor. Proc Nat Acad Sci USA 88: 7491-7495.
52. Ward AS, Li DH, Luedtke RR, Emmett-Oglesby MW (1996): Variations in the cocaine self-administration of inbred strains of rats using a progressive ratio schedule. Psycopharm 127: 204-212.
53. Williams GV, Goldman-Rakic PS (1996): Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376: 572-575.
54. Woolverton WL, Johnson KM (1992): Neurobiology of cocaine abuse. TiPS 13: 193-195.
55. Woolverton WL, Virus RM (1989): The effects of a D1 and a D2 dopamine antagonist on behavior maintained by cocaine or food. Pharmacol Biochem Behav 32: 691-699.
56. Xu M, Hu XT, Cooper DC, Moratall R, Graybiel AM, White FJ, Tonegawa S (1994): Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell 79: 945-955.
57. Yokel RA, Wise RA (1978): Amphetamine-type reinforcement by dopamine agonists in the rat. Psychopharmacology 58: 289-297.
58. Zhou Q-Y, Grandy DK, Thambi L, Kushner JA, Van Tol HHM, Cone R, Pribnow D, Salon J, Bunzow JR, Civelli O (1990): Cloning and expression of human and rat D1 dopamine receptors. Nature 347: 76-81.